Rallybio Further Strengthens Leadership Team with Addition of Steven Ryder, MD, FACP
R&D Executive with Proven Track Record in the Biopharmaceutical Industry
FARMINGTON, Conn.–(BUSINESS WIRE)– Rallybio LLC, a development-stage biotechnology company, today announced that it continues to expand its drug acquisition and development capabilities with the addition of Steven Ryder, MD, FACP. Dr. Ryder, a seasoned R&D executive, will assist in advancing Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
“As a company with plans for significant growth over the next few years, we will benefit greatly from Steve’s extensive leadership in global healthcare development,” said Martin Mackay, PhD, co-founder of Rallybio. “Steve’s track record in the rare disease space further expands our ability to identify and bring forward transformative therapeutics.”
Dr. Ryder brings to Rallybio more than 30 years of leadership expertise, having been instrumental in the development of more than a dozen therapeutics, including Norvasc, Zoloft, Vfend, Geodon, Myrbetriq, and Strensiq. Most recently, Dr. Ryder served as Senior Vice President, Chief Development Officer at Alexion Pharmaceuticals, where he led the global development, registration, and approval of new drug candidates for rare diseases, and assisted in expanding teams to accommodate the growth of the company. Prior to Alexion, Dr. Ryder was founding President, Astellas Pharma Global Development and spent 21 years in positions of increasing clinical development leadership at Pfizer.
“The collective expertise of the leadership and employees at Rallybio, and their overwhelming compassion for patients, offers great opportunity to achieve the goal of developing life-transforming treatments for those suffering with rare and ultra-rare disease,” said Dr. Ryder.
Dr. Ryder is the past-President and Board member of the American Society of Clinical Pharmacology and Therapeutics, has served as the industry representative on the FDA’s Endocrinologic and Metabolic Drug Advisory Committee, and has held leadership positions within the Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Ryder received his MD from the Icahn School of Medicine at Mount Sinai.
Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio has earned the support of highly-respected investors in the bioscience sector and announced in April 2018 that it had secured $37.0 million in a Series A funding led by 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, with additional public-sector participation from Connecticut Innovations. The Company is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program. For more information, please visit www.rallybio.com.